Immunome is a biotechnology company that develops next-generation cancer immunotherapies. The company's proprietary discovery engine identifies novel cancer targets and develops antibody-based therapies to treat cancer. Immunome's lead product candidate, IMM-BCP-01, is a first-in-class cancer immunotherapy that targets a novel cancer antigen. The company is headquartered in Philadelphia, Pennsylvania.